



Division of
Johnson & Johnson
Vision Care, Inc.

RECEIVED
CENTRAL FAX CENTER

MAY 13 2004

CONFIDENTIAL
FACSIMILE TRANSMISSION SHEET

OFFICIAL

DATE: May 13, 2004

TO: Examiner Rachel M. Bennett
Art Unit 1615

FAX: 703-872-9306

FROM: Karen Harding, Patent Attorney

PHONE: 904-443-3074
FAX #: 904-443-3078

Re: Response to 2-13-04 Office Action
Serial Number: 10/029,526
Our Docket Number: VTN 570

Please see attached.

Total Pages Sent: 4 (including this cover sheet)

Please call Kate Willan at 443-1159 if you do not receive all of the pages in this transmission. Thank you.

This facsimile transmission cover sheet and any documents which may accompany it, contains information from Vistakon®, Division of Johnson & Johnson Vision Care, Inc., which is intended only for the use of the individual or entity to which it is addressed, and which may contain information that is privileged, confidential and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us collect to arrange for the destruction of the communication or its return to us at our expense.

*Note: refax - Title on the fist page of
the prior fax was incorrect.*

Docket No. VTN-570

RECEIVED
CENTRAL FAX CENTER

MAY 13 2004

OFFICIAL

Applicants : David C. Turner, et al.
Serial No. : 10/029,526
Filed : December 21, 2001
Title: ANTIMICROBIAL LENSES AND METHODS OF THEIR USE
Art Unit : 1615
Examiner : Rachel M. Bennett

I hereby certify that this correspondence is being facsimile transmitted
to the Patent and Trademark Office, Fax No. (703) 872-9306 on

May 13, 2004
(Date of Deposit)

Karen Harding
Name of applicant, assignee, or Registered Representative

(Signature)

May 13, 2004
(Date of Signature)

Honorable Commissioner of Patents
Washington, D.C. 20231

Response under 35 CFR 1.111

Dear Sir:

Amendments to the Claims there are no amendments to the claims.

Remarks/Arguments begin on page 2 of this paper.